
Quarterly report 2022-Q4
added 02-09-2023
Quotient Limited Net Debt 2011-2026 | QTNT
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 103 M | 266 M | 208 M | 70.6 M | 92 M | -15.2 M | -22.3 M | 8.25 M | -714 K | -1.26 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 266 M | -22.3 M | 70.9 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Agilent Technologies
A
|
1.24 B | $ 115.55 | 3.81 % | $ 35.1 B | ||
|
CareDx, Inc
CDNA
|
-39.2 M | $ 20.81 | 0.05 % | $ 1.11 B | ||
|
Co-Diagnostics
CODX
|
-10.6 M | $ 1.55 | 1.31 % | $ 2.06 M | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 24.49 | 1.03 % | $ 680 M | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 15.19 | 2.64 % | $ 459 M | ||
|
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 118.33 | 1.86 % | $ 9.76 B | ||
|
Illumina
ILMN
|
-494 M | $ 126.74 | 5.29 % | $ 20.2 B | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 166.97 | 1.91 % | $ 8.28 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
Lantheus Holdings
LNTH
|
213 M | $ 84.62 | 4.25 % | $ 5.71 B | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 418.66 | 1.23 % | $ 12.1 B | ||
|
Guardant Health
GH
|
1.15 B | $ 87.08 | 4.4 % | $ 10.9 B | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 26.34 | 2.95 % | $ 20 B | ||
|
Myriad Genetics
MYGN
|
115 M | $ 4.75 | 1.5 % | $ 440 M | ||
|
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.98 | -0.5 % | $ 8.76 M | ||
|
NeoGenomics
NEO
|
187 M | $ 9.26 | 3.35 % | $ 1.19 B | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
-1.94 M | $ 2.18 | 0.93 % | $ 5.01 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 256.8 | -0.13 % | $ 21.4 B | ||
|
National Research Corporation
NRC
|
71.3 M | $ 16.46 | -0.48 % | $ 368 M | ||
|
Celcuity
CELC
|
-28.1 M | $ 121.35 | 1.97 % | $ 5.67 B | ||
|
Natera
NTRA
|
-177 M | $ 206.16 | 5.86 % | $ 20.3 B | ||
|
Neogen Corporation
NEOG
|
751 M | $ 9.4 | 4.33 % | $ 2.04 B | ||
|
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | ||
|
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 194.2 | 2.58 % | $ 21.6 B | ||
|
OpGen
OPGN
|
711 K | - | -16.95 % | $ 1.54 M | ||
|
Organovo Holdings
ONVO
|
-10.4 M | - | -2.3 % | $ 19.4 M | ||
|
PerkinElmer
PKI
|
2.3 B | - | -0.91 % | $ 14.7 B | ||
|
Exagen
XGN
|
-8.73 M | $ 2.9 | 5.07 % | $ 62.5 M | ||
|
Precipio
PRPO
|
-2.19 M | $ 30.9 | 3.21 % | $ 49.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
-76 M | $ 17.0 | 4.68 % | $ 179 M | ||
|
Personalis
PSNL
|
-48.8 M | $ 5.52 | 9.52 % | $ 327 M |